S038 JAK Inhibitors: A New Frontier in Dermatology
DESCRIPTION
Janus kinase (JAK) inhibitors are a relatively new class of medicines in dermatology and are increasingly important due to their unmatched therapeutic potential across inflammatory skin diseases. The application of JAK inhibitors to dermatologic diseases will be presented, including the results of clinical trials and case series. The safety profile of JAK inhibitors will be discussed in detail. The audience for this session will be dermatologists who care for patients with alopecia areata, atopic dermatitis and prurigo nodularis, granuloma annulare and sarcoidosis, lichen planus, lichen planopilaris, lupus and dermatomyositis and other CTD, hidradenitis suppurativa, and vitiligo.
LEARNING OBJECTIVES
Describe an important class of medications with unparalleled breadth of application in dermatology.
Utilize JAK inhibitors for the treatment of alopecia areata, atopic dermatitis, dermatomyositis, granuloma annulare and sarcoidosis, hidradenitis suppurativa, lichen planus, lichen planopilaris, and vitiligo.
Summarize the safety profile of JAK inhibitors and differentiate the safety profile among disease states.
SCHEDULE
1:00 PM
Why JAK Inhibitors Are So Broadly Effective
Brett King, MD, PhD, FAAD
1:10 PM
JAK Inhibitors for Lichen Planus and Lichen Planopilaris (and Frontal Fibrosing Alopecia)
Maryanne Makredes Senna, MD, FAAD
1:25 PM
JAK Inhibitors for Dermatomyositis, Lupus, and SAVI
Ruth Ann Vleugels, MD, MBA, MPH, FAAD
1:40 PM
Q&A
Maryanne Makredes Senna, MD, FAAD, Ruth Ann Vleugels, MD, MBA, MPH, FAAD
1:50 PM
JAK Inhibitors for Granuloma Annulare and Sarcoidosis
William Damsky, PhD, MD, FAAD
2:05 PM
JAK Inhibitors for Atopic Dermatitis and Prurigo Nodularis
Raj J. Chovatiya, MD, PhD, FAAD
2:20 PM
Q&A
Raj J. Chovatiya, MD, PhD, FAAD, William Damsky, PhD, MD, FAAD
2:30 PM
JAK Inhibitors for Vitiligo
Thierry Passeron, MD, PhD
2:45 PM
JAK Inhibitors for Alopecia Areata
Brittany Craiglow, MD, FAAD
3:00 PM
Q&A
Brittany Craiglow, MD, FAAD, Thierry Passeron, MD, PhD
3:10 PM
JAK Inhibitors for Hidradenitis Suppurativa and Pyoderma Gangrenosum
Martina J. Porter, MD, FAAD
3:25 PM
Understanding the Safety Profile of JAK Inhibitors
Brett King, MD, PhD, FAAD
3:45 PM
Q&A
Brett King, MD, PhD, FAAD, Martina J. Porter, MD, FAAD
DIRECTOR
Brett King, MD, PhD, FAAD
DISCLOSURES
Brett King, MD, PhD, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Amgen – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Aquestive Therapeutics – Consultant (1099 relationship)(Fees); BiologicsMD, Inc. – Consultant(Stock Options); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Eli Lilly and Company – Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Galderma – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Fees); Imagene Bio – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant(Fees), Data Safety Monitoring Board(Fees); Leo Pharma – Advisory Board(Honoraria); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Q32 Bio Inc. – Consultant (1099 relationship)(Fees); Regeneron – Advisory Board(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Sanofi Genzyme – Speaker(Honoraria); Soterios Pharma – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant(Fees), Investigator(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); TWi Biotechnology, Inc. – Consultant(Fees);